Biogen’s FDA Victory Changes the Game for Alzheimer’s Treatment
Regulators embraced a controversial theory of the disease. That could open the gates for yet more therapies.
Regulators embraced a controversial theory of the disease. That could open the gates for yet more therapies.
The company reported a first-quarter 2021 adjusted income per share of $0.82 per share, which beat analysts’ expectations.
Don’t Despair, Bitcoin Lovers! There Are Worse Assets BloombergQuint
KKR & Co.’s Independence Energy and Contango Oil & Gas Co. are near an agreement to combine in an…
HQY earnings call for the period ending April 30, 2021.